RecruitingNot ApplicableNCT06493968

Role of Uterotonics in Reducing Intraoperative Blood Loss in Patients With PASD Undergoing Cesarean Hysterectomy

Role of Uterotonics in Reducing Intraoperative Blood Loss in Patients With Placenta Accrete Spectrum Disorders Undergoing Cesarean Hysterectomy


Sponsor

Cairo University

Enrollment

70 participants

Start Date

Jul 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Objectives: To evaluate the effect of oxytocin in reducing intraoperative blood loss in patients with PAS disorders planned for cesarean hysterectomy.


Eligibility

Sex: FEMALEMin Age: 20 YearsMax Age: 40 Years

Inclusion Criteria6

  • Pregnancy of singleton living fetus
  • Previous one or more cesarean sections
  • Gestational age: > 32 weeks
  • The following ultrasound markers such as "loss of clear retroplacental translucency", "myometrial thinning", "abnormal lacunae", "irregular bladder wall", "utero-vesicalhypervascularity".
  • Preoperative hemoglobin more than 10 gm/dl
  • Cases with PAS that will undergoing CS Hysterectomy

Exclusion Criteria5

  • Maternal medical disorders e.g.: coagulation defects, cardiac diseases etc.….
  • Any known or reported hypersensitivity to the used medication.
  • All cases with spontaneous placental separation at laparotomy.
  • All patients undergoing conservative management of PAS.
  • All cases which necessitate emergency termination.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGoxytocin

Uterotonics will be given in the form of an IV bolus of 10 units of oxytocin immediately with the uterine incision

OTHERplacebo

IV bolus of normal saline immediately with the uterine incision


Locations(1)

Cairo University

Cairo, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06493968


Related Trials